Immunogenetics of Outcomes Disparities After Allogeneic HCT
Immunogenetics of Outcomes Disparities After Allogeneic HCT
批准号:
10659539
负责人:
Effie W Petersdorf
金额:
$44.29万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-05-15 至 2028-04-30
关键词:
AfricanAfrican AmericanAllogenicAsianAsian AmericansBindingCaucasiansCellsCharacteristicsClinicalComplexCountryDataDisease-Free SurvivalDisparityDonor SelectionDonor personExonsFailureFutureGene ExpressionGenesGeneticGenetic PolymorphismGenotypeGoalsGraft RejectionHLA-B AntigensHLA-DQ AntigensHaplotypesHematopoietic NeoplasmsHispanicHispanic AmericansHistocompatibilityHomologous TransplantationHumanImmunogeneticsInvestigationLaboratoriesLifeLigandsMethodsMicaModelingNatureOutcomePathway interactionsPatient CarePatientsPeptide Leader SequencesPeptidesPhasePopulationRaceRelapseRiskRisk AssessmentRoleShapesSupplementationSurvival RateTissuesTransplant RecipientsTransplantationUmbilical Cord Blood TransplantationVariantWorkcancer cellcancer health disparitycaucasian Americancell transformationgraft vs host diseasehematopoietic cell transplantationhigh riskimprovedindividualized medicineinnovationmortalitynon-geneticnovelopen dataoutcome disparitiesprospectiveracial disparityracial diversityracial populationreceptorreceptor expressionrelapse risksuccesssurvival disparitysurvival outcomesurvivorshiptumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Nowhere are racial disparities in cancer survival rates as striking as in hematopoietic cell transplantation (HCT)
because both the patient and the donor contribute to survival outcomes. HLA genetic features are ancestry-
informative. When ancestry-specific features are accounted for, survival disparities are diminished but major
gaps still exist between African, Hispanic, Asian and Caucasian American transplant patients. Relapse of the
blood cancer remains the chief cause of transplant failure; however, the role for the NKG2 axis, the major anti-
tumor pathway, in relapse and survival after HCT is ill-defined. The unmet need is to identify the NKG2
ligand/receptor immunogenetic factors involved in relapse and which account for disparities in survival. If these
factors were known, then prospective risk-assessment of the patient’s germline and optimized donor selection
could diminish or even abolish survival disparities across US populations. We have elucidated the survival
disparities between HCT patients of African, Hispanic, Asian and Caucasian American ancestry, and have
identified key ancestry-informative NKG2 ligand and receptor variants that impact gene expression and
survival. We propose to identify ancestry-specific NKG2 ligand and receptor missense and regulatory variation
that account for survival in each race, and examine the impact of optimal features across races to minimize or
abolish survival disparities in HCT. The specific aims are to 1) identify mechanisms that underpin NKG2
ligand/receptor expression variation in diverse races; 2) define NKG2 ligand/receptor ancestry-informative
variation for survival in each race, and 3) define survivorship disparities with ancestry-specific “ideal”
immunogenetic characteristics. The goals will be achieved through systematic analysis of NKG2
ligand/receptor variation to identify functional variants, followed by large-scale genotyping of related donor,
unrelated donor and cord blood transplant patients and donors and identification of ideal features that inform
survival within each race. The extent to which survival disparities may be diminished or even abolished through
transplantation of patients and donors with ideal characteristics will be defined. The information from this
project will increase the success of transplantation for all patients in need of this life-saving therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immunogenetics of Outcomes Disparities after Allogeneic HCT
-
批准号:10177961
-
项目类别:
-
资助金额:$29.35万
-
财政年份:2018
-
负责人:Effie W Petersdorf
-
依托单位:
Immunogenetics of Outcomes Disparities after Allogeneic HCT
-
批准号:10441227
-
项目类别:
-
资助金额:$39.45万
-
财政年份:2018
-
负责人:Effie W Petersdorf
-
依托单位:
Immunogenetics of Outcomes Disparities after Allogeneic HCT
-
批准号:10601325
-
项目类别:
-
资助金额:$9.32万
-
财政年份:2018
-
负责人:Effie W Petersdorf
-
依托单位:
Immuno and Epigenetics of Hematopoietic Cell Transplantation
-
批准号:10216189
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2017
-
负责人:Effie W Petersdorf
-
依托单位:
Immuno and Epigenetics of Hematopoietic Cell Transplantation
-
批准号:10660131
-
项目类别:
-
资助金额:$62.31万
-
财政年份:2017
-
负责人:Effie W Petersdorf
-
依托单位:
Immuno and Epigenetics of Hematopoietic Cell Transplantation
-
批准号:9361832
-
项目类别:
-
资助金额:$66.0万
-
财政年份:2017
-
负责人:Effie W Petersdorf
-
依托单位:
Immuno and Epigenetics of Hematopoietic Cell Transplantation
-
批准号:9980803
-
项目类别:
-
资助金额:$59.85万
-
财政年份:2017
-
负责人:Effie W Petersdorf
-
依托单位:
Immuno and Epigenetics of Hematopoietic Cell Transplantation
-
批准号:10602899
-
项目类别:
-
资助金额:$19.64万
-
财政年份:2017
-
负责人:Effie W Petersdorf
-
依托单位:
Immunogenetics of Graft-Versus-Host Disease
-
批准号:8277818
-
项目类别:
-
资助金额:$37.96万
-
财政年份:2011
-
负责人:Effie W Petersdorf
-
依托单位:
Genetic Mechanisms of Survivorship Disparities after Unrelated HCT
-
批准号:8521195
-
项目类别:
-
资助金额:$30.07万
-
财政年份:2011
-
负责人:Effie W Petersdorf
-
依托单位:
Genetic Mechanisms of Survivorship Disparities after Unrelated HCT
-
批准号:8910666
-
项目类别:
-
资助金额:$32.97万
-
财政年份:2011
-
负责人:Effie W Petersdorf
-
依托单位:
Genetic Mechanisms of Survivorship Disparities after Unrelated HCT
-
批准号:8195326
-
项目类别:
-
资助金额:$37.0万
-
财政年份:2011
-
负责人:Effie W Petersdorf
-
依托单位:
Genetic Mechanisms of Survivorship Disparities after Unrelated HCT
-
批准号:8319381
-
项目类别:
-
资助金额:$33.16万
-
财政年份:2011
-
负责人:Effie W Petersdorf
-
依托单位:
Genetic Mechanisms of Survivorship Disparities after Unrelated HCT
-
批准号:8707404
-
项目类别:
-
资助金额:$34.07万
-
财政年份:2011
-
负责人:Effie W Petersdorf
-
依托单位:
Hematopopietic Stem Cell Transplantation
-
批准号:7899701
-
项目类别:
-
资助金额:$63.72万
-
财政年份:2009
-
负责人:Effie W Petersdorf
-
依托单位:
Clinical Significance of MHC Haplotypes in HCT
-
批准号:8212577
-
项目类别:
-
资助金额:$33.42万
-
财政年份:2008
-
负责人:Effie W Petersdorf
-
依托单位:
Clinical Significance of MHC Haplotypes in HCT
-
批准号:7579815
-
项目类别:
-
资助金额:$34.45万
-
财政年份:2008
-
负责人:Effie W Petersdorf
-
依托单位:
Clinical Significance of MHC Haplotypes in HCT
-
批准号:8024567
-
项目类别:
-
资助金额:$33.42万
-
财政年份:2008
-
负责人:Effie W Petersdorf
-
依托单位:
Clinical Significance of MHC Haplotypes in HCT
-
批准号:7463223
-
项目类别:
-
资助金额:$34.45万
-
财政年份:2008
-
负责人:Effie W Petersdorf
-
依托单位:
Clinical Significance of MHC Haplotypes in HCT
-
批准号:7758821
-
项目类别:
-
资助金额:$34.45万
-
财政年份:2008
-
负责人:Effie W Petersdorf
-
依托单位:
海外基金